Marie Zhu

Marie Zhu

Company: Remegen

Job title: Chief Technology Officer


AIDEXI®(Disitamab Vedotin): A 10-Year Development Journey and Its CMC Strategy for Accelerated BLA Filing 12:00 pm

• Disitamab vedotin was the first ADC drug approved for clinical trials as well as for clinical applications in China. • Its efficacy has been validated in multiple indications (gastric cancer, urothelial cancer, and breast cancer) with a favorable safety profile. • This presentation will show non-clinical and clinical data in developing Disitamab vedotin and…Read more

day: day 2 track 3

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.